

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No.370; Bortezomib for untreated mantle cell lymphoma

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> • Janssen-Cilag (bortezomib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • African Caribbean Leukaemia Trust (ACLT) • Anthony Nolan • Bloodwise • Cancer Black Care • Cancer Equality • Cancer52 • DKMS • HAWC • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Leukaemia Cancer Society • Leukaemia CARE • Lymphoma Action • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Muslim Council of Britain • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Committee for Standards in Haematology (BCSH) • British Psychosocial Oncology Society (BPOS) • British Society for Haematology • British Geriatrics Society • Cancer Research UK • Royal College of General Practitioners 	<p><u>General commentators</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee • All Wales Therapeutics and Toxicology Centre <p><u>Comparators</u></p> <ul style="list-style-type: none"> • Aspen (chlorambucil) • Accord Healthcare (bendamustine, cytarabine, doxorubicin, fludarabine) • Baxter Healthcare (cyclophosphamide) • Dr Reddy's Laboratories (bendamustine) • Hospira (cytarabine, vincristine) • medac UK (bendamustine, doxorubicin) • Napp Pharmaceuticals (bendamustine, rituximab) • Pfizer (cytarabine, doxorubicin) • Roche Products (rituximab) • Sandoz (cyclophosphamide, fludarabine, rituximab)

<ul style="list-style-type: none"> • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Society of Medicine • UK Clinical Pharmacy Association • Royal Pharmaceutical Society • UK Health Forum • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • Welsh Government • NHS Vale Royal CCG • NHS Leeds North CCG 	<ul style="list-style-type: none"> • Seacross Pharmaceuticals (doxorubicin) • Zentiva (bendamustine) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Haematological Malignancies Group • Institute of Cancer Research • Leuka • Leukaemia Busters • Lymphoma Research Trust • National Cancer Research Institute • National Cancer Research Network • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales
---	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

MTA Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal.

These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.